Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-07

Study Completion Date

2028-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies. In recent years, repetitive transcranial magnetic stimulation (rTMS) has shown increasing success. A recent randomized, double-blind, sham-controlled, phase 2 demonstrated promising results from a 24-week rTMS treatment protocol targeting the precuneus. This brain region is considered a main hub of the human brain connectome and a prominent area of AD pathology. The results showed stable cognitive performance and increased brain activity in the treatment group, whereas the sham group worsened. A replication study is planned to further investigate the working mechanism of precuneus-rTMS in AD and to improve understanding of its therapeutic potential.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transcranial Magnetic Stimulation in Mild Cognitive Impairment and Alzheimer Disease

NCT04771845

Alzheimer Disease Mild Cognitive Impairment

COMPLETED

TMS in Preclinical and Prodromal AD: Modulation of Brain Networks and Memory

NCT04294888

Alzheimer Disease Mild Cognitive Impairment Aging

UNKNOWN NA

Investigating the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment for Alzheimer's Disease

NCT02908815

Alzheimer's Disease

COMPLETED NA

Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease

NCT00753662

Alzheimer's Disease

UNKNOWN PHASE2

Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)

NCT06597942

Alzheimer&Amp;Amp;#39;s Disease Alzheimer Disease Dementia Alzheimer Type +4 more

RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease Alzheimer Disease, Early Onset

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Verum

Verum rTMS

Group Type EXPERIMENTAL

repetitive transcranial magnetic stimulation

Intervention Type DEVICE

20 Hz repetitive transcranial magnetic stimulation targeted at the precuneus

Sham

sham rTMS

Group Type SHAM_COMPARATOR

sham repetitive transcranial magnetic stimulation

Intervention Type DEVICE

20 Hz sham repetitive transcranial magnetic stimulation targeted at the precuneus

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

repetitive transcranial magnetic stimulation

20 Hz repetitive transcranial magnetic stimulation targeted at the precuneus

Intervention Type DEVICE

sham repetitive transcranial magnetic stimulation

20 Hz sham repetitive transcranial magnetic stimulation targeted at the precuneus

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Biomarker-supported Alzheimer's disease (abnormal CSF p-tau/Aβ42 ratio of \> 0.023 or amyloid PET positive).
* Between 50 and 85 years old.
* Clinical Dementia Rating (CDR) score of 0.5 or 1.
* Mini-Mental State Examination (MMSE) score between 18 and 26.
* Presence of a caregiver.

Exclusion Criteria

* Medical history of neurodegenerative diseases other than AD, stroke, or epilepsy.
* Severe psychiatric dysregulation, hampering successful study participation and leading to possible cognitive impairment. Eligibility for participation will be based on clinical evaluation by an expert neurologist and/or psychiatrist.
* Extensive cerebrovascular damage on MRI classified as Fazekas level 2 or 3. Patients with abnormalities classified as Fazekas level 3 are excluded. For Fazekas level 2, patient's eligibility for participation will be evaluated by an expert neurologist.
* Presence of metal in the head or cranial/thoracic implants, including cochlear implants.
* Cholinesterase inhibitors with unstable dosage in the last 2 months.
* Extreme claustrophobia or metallic objects in or on the body, preventing MRI and MEG examination.
* Previous rTMS treatment (for blinding reasons).

Minimum Eligible Age

50 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No